Burns
Also known as: Trauma, Injury, Destruction, Traumatic
Methodology & AI Transparency ⓘ
Burns Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A burn is damage to your body's tissues caused by heat, chemicals, electricity , sunlight , or radiation .
- 2 Real-world patient consensus: Clinical coding for Burns uses ICD-10 T30.0 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Primary evaluation for Burns incorporates dermoscopy or punch in Burns (T30.0: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Burns monitoring tracks Fasting Lipids & in Burns (T30.0: ALT (if systemic) toward Within baseline reference limits (T30.0).
Ask our AI Specialists anything about Burns
What Is Burns?
A burn is damage to your body's tissues caused by heat, chemicals, electricity , sunlight , or radiation . Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury , caused by breathing smoke. There are three types of burns: First-degree burns damage only the outer layer of skin Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath Burns can cause swelling, blistering, scarring and, in serious cases, shock , and even death.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Burns (T30.0) center on cutaneous immune skewing in Burns (T30.0: (Th2/IL-4/IL-13 in atopic). Cross-referenced with NIH MeSH (Burns), targeted skin & dermatology interventions aim to normalize Fasting Lipids & in Burns (T30.0: ALT (if systemic).
Common Symptoms & Clinical Signs
- • First-degree burns damage only the outer layer of skin
- • Second-degree burns damage the outer layer and the layer underneath
- • Presentation of Burns (T30.0): recurrent flares triggered in Burns (T30.0: by UV exposure,)
- • Secondary Burns clinical sign: persistent erythematous plaques, in Burns (T30.0: scaly patches, pruritic)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Burns Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T30.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Burns (T30.0: ALT (if systemic) | Within baseline reference limits (T30.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Burns (T30.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (T30.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Burns (T30.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (T30.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Burns
Treatment selection for Burns depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Burns)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of imiquimod in the management of lentigo: What a 283-Participant Study Found Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 37114291 ↗ |
| Can This Approach Help? Inside the Latest Research on Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Complete ER was higher in the NexoBrid versus the GV group (93% vs 4%; P 90% of burn patients, reduced surgery and blood loss. Journal of burn care & research : official publication of the American Burn Association • 2024-03-04 • Phase III Randomized Trial | N = 75 | 88/100 | PMID 37715999 ↗ |
| Can This Approach Help? Inside the Latest Research on Polymer oxygenated alginate dressings for healing skin graft donor areas: A phase Our results demonstrate that POA dressing is safe and clinically effective for treating split-thickness skin graft donor site wounds. Burns : journal of the International Society for Burn Injuries • 2026-04-15 • Phase III Randomized Trial | N = 69 | 82/100 | PMID 41713054 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in There was a high success rate observed in the study, which may be attributable to the large percentage of adult female acne patients enrolled. Journal of drugs in dermatology : JDD • 2013-03-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 23545909 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase 3, open-label, controlled, randomized, multicenter trial evaluating the Both coprimary endpoints were achieved. Burns : journal of the International Society for Burn Injuries • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34099322 ↗ |
Burns Patient Community & “People Like Me” Threads
Filter Burns community threads and patient logs by age, biological sex, dosage, and treatment duration.